Compare CAC & DRUG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CAC | DRUG |
|---|---|---|
| Founded | 1875 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Pharmaceuticals and Biotechnology |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 801.9M | 856.4M |
| IPO Year | 1997 | N/A |
| Metric | CAC | DRUG |
|---|---|---|
| Price | $50.31 | $76.68 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 6 |
| Target Price | $45.50 | ★ $106.75 |
| AVG Volume (30 Days) | 105.6K | ★ 125.9K |
| Earning Date | 01-27-2026 | 02-10-2026 |
| Dividend Yield | ★ 3.35% | N/A |
| EPS Growth | ★ 6.08 | N/A |
| EPS | ★ 3.84 | N/A |
| Revenue | ★ $233,489,000.00 | N/A |
| Revenue This Year | $19.32 | N/A |
| Revenue Next Year | $5.90 | N/A |
| P/E Ratio | $13.05 | ★ N/A |
| Revenue Growth | ★ 31.62 | N/A |
| 52 Week Low | $34.53 | $23.18 |
| 52 Week High | $51.57 | $123.75 |
| Indicator | CAC | DRUG |
|---|---|---|
| Relative Strength Index (RSI) | 66.39 | 43.97 |
| Support Level | $49.36 | $72.08 |
| Resistance Level | $51.57 | $81.00 |
| Average True Range (ATR) | 1.71 | 4.85 |
| MACD | 0.37 | -1.57 |
| Stochastic Oscillator | 87.69 | 26.02 |
Camden National Corporation is a banking solutions provider in the United States. Its core business is providing commercial banking products to individuals and corporates. Its consumer and commercial banking services entail services such as loans and deposits, savings and online banking, treasury management solutions and non-profit products to consumer, institutional, municipal, non-profit and commercial customers. The company also offers investment management and fiduciary services.
Bright Minds Biosciences Inc is focused on developing novel, transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult-to-treat disorders such as resistant epilepsy, treatment-resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.